

**INITIATIVE ON METHODS, MEASUREMENT, AND PAIN ASSESSMENT IN  
CLINICAL TRIALS**

**IMPACT-XVI**

**RECOMMENDATIONS FOR PATIENT PHENOTYPING IN PHASE 2 AND 3 ANALGESIC CLINICAL  
TRIALS**

**JUNE 14-15, 2013**

**SOFITEL**

**WASHINGTON, DC**

***THURSDAY, JUNE 13***

**7:00 PM RECEPTION AND DINNER (at the Westin)**

***FRIDAY, JUNE 14***

**7:30–8:00 AM CONTINENTAL BREAKFAST**

**8:00–8:30 AM Welcome and introductions**

- *Dennis Turk, PhD*

**8:30–9:15 AM Patient-reported pain and symptom measures, including psychological and sleep measures for Phase 2 and 3 trials**

- *Robert Edwards, PhD*

**9:15–9:45 AM PROMIS measures and the NIH tool box for Phase 2 and 3 trials**

- *Raymond Dionne, DDS, PhD*

**9:45–10:15 AM COFFEE BREAK**

**10:15–12:15 PM Panel discussion and Q & A on patient-reported measures for Phase 2 and 3 trials**

- *moderator: Dennis Turk*
- *Laurie Burke, RPh, MPH; Ray Dionne; Rob Edwards; Roger Fillingim, PhD; Ajay Wasan, MD*

**12:15–1:15 PM LUNCH**

**1:15–2:00 PM Quantitative sensory testing (QST) for Phase 2 trials**

- *Per Hansson, MD, PhD*

**2:00–2:30 PM Conditioned pain modulation (CPM) / descending noxious inhibitory controls (DNIC) for Phase 2 and 3 trials**

- *Simon Haroutiunian, PharmD*

**2:30–3:00 PM COFFEE BREAK**

**3:00–5:00 PM Panel discussion and Q & A on QST and CPM/DNIC for Phase 2 trials**

- *moderator: Andrew Rice, MD*
- *Lars Arendt-Nielsen, Dr Med Sci, PhD; Nadine Attal, MD, PhD; Ralf Baron, MD; Per Hansson; Simon Haroutiunian*

**7:00–9:00 PM**

**DINNER**

**SATURDAY, JUNE 15**

**7:30–8:00 AM**

**CONTINENTAL BREAKFAST**

**8:00–8:45 AM**

**Response to pharmacologic challenge in Phase 2 and 3 trials**

- *Martin Angst, MD*

**8:45–9:30 AM**

**Clinical testing and QST in Phase 3 trials**

- *Roy Freeman, MD*

**9:30–10:00 AM**

**COFFEE BREAK**

**10:00–12:00 PM**

**Panel discussion and Q & A on pharmacologic challenge, clinical testing, and QST in Phase 3 trials**

- *moderator: Nathaniel Katz, MD*
- *Martin Angst; Roy Freeman; Bob Rappaport, MD; Joachim Scholz, MD; David Yarnitsky, MD*

**12:00–1:00 PM**

**LUNCH**

**1:00–4:00 PM**

**Group discussion: consensus recommendations for patient phenotyping in Phase 2 and 3 analgesic trials**

- *moderators: Bob Dworkin and Dennis Turk*
- *with continuous coffee service*